Overexpression of IL6 was closely related to poor tumor prognosis.[25] This study showed that after treatment in the observation group, the level of IL6 in the serum of patients decreased, suggesting that the combined effect of FZLZD with XELOX plus sintilimab regimen in the fight against GC may be related to the reduction of the expression of IL6. The gene discussed is IL6; the disease is gastric cancer.